Abstract
Adjuvant treatments of non-small cell lung cancer (radiotherapy and chemotherapy) before or after surgery, have been tested in numerous trials, more particularly as regards postoperative chemotherapy. For a long time the results were disappointing, and in randomized studies none of the therapeutic regimens prescribed could improve the patient’s survival. New hopes of advances in this matter were raised by Goldie and Coldman [1] whose mathematical concept recommended a systemic treatment applied as early as possible in cases with localized tumour. The advent of Platinum [2], the results obtained in metastatic tumours by some associations with Platinum and those obtained in localized tumours by chemotherapy-radiotherapy [3] have been promising. Many phase II studies have shown that surgery was feasible after 2 or 3 cycles of chemotherapy [4, 8] even thought 1 of them [9] had observed a high rate of progression after chemotherapy which prevented surgery.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Goldie DH, Coldmann AJ (1979) A mathematic model for relating the lung sensibility of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733
Albain K, Growley Y, Leblanc M et al (1990) Does cisplatin-based therapy improved survival in extensive non-small cell lung cancer ? Southwest oncology Group (SWOG) Studies. Proceedings ASCO, A 887
Dillman R, Seagren S, Propert K et al (1988) Protochemotherapy improves survival in regional non-small cell lung cancer (NSCLC). Proceedings ASCO, A 753
Burkes R, Ginsberg R, Shphred S et al (1988) Phase II pilot program of NeoAd j uvant chemotherapy for stade III (T 1–3, N2, MO) unresectable non-small cell lung cancer. Proc Lung Cancer 4 (abstr) n° 8.2.28
Gralla RJ, Kris MG, Martini M, Zaman M (1988) A Neo-Adjuvant in stage IIIA non-small cell lung cancer in patients with clinically apparent mediastinal node involvement with MVP chemotherapy (Mitomycine + Vinca Alkaloid + Cisplatin). Proc Lung Cancer 4 (abstr) n° 8.2.05
Curie D, Miles D, Drake J et al (1990) Mitomycine, Ifosfamide and Cisplatin in non-small cell lung cancer. Cancer Chemother Pharmacol 25: 380–381
Artal A, Garrido P, Baron M et al (1990) Randomized trial comparing Ifosfamide, Cisplatin, Mitomycine v.s. Ifosfamide, Cisplatin-Vindesine in patients with advanced non-small cell lung cancer. Proceeding ASCO, A 979
Rosell R, Gomez-Codina J, Camps C et al (1992) Favorable outcome and anenploidy reversion following Neo-Adjuvant chemotherapy in stage IIIA non-small cell lung cancer (NSCLC). Proceeding ASCO, A 954
Dautzenberg B, Benichou J, Allard Ph, Lebeau B, Coetmeur D, Brechot JM, Postal M, Chastang Cl (1990) Failure of the perioperative PCV Neo-Adjuvant Polychemotherapy in resectable bronchogenic non-small cell carcinoma. Results from a randomized phase II trial. Cancer 65: 2435–2441
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag France
About this paper
Cite this paper
Depierre, A. et al. (1994). Phase III randomized study of Neo-Adjuvant chemotherapy surgery in non-small cell lung cancer (NSCLC) preliminary results. In: Banzet, P., Holland, J.F., Khayat, D., Weil, M. (eds) Cancer Treatment An Update. Springer, Paris. https://doi.org/10.1007/978-2-8178-0765-2_72
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0765-2_72
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0767-6
Online ISBN: 978-2-8178-0765-2
eBook Packages: Springer Book Archive